RECRUITING

Action Regulation Behavioral

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Parkinson's disease (PD) is a neurodegenerative disorder involving a part of the brain that is responsible for motor control, which not only results in changes or disruptions in movement, but also cognitive dysfunctions. Given that the decline of muscle control such as tremors, with difficulty walking or the ability to switch tasks once in movement, greatly affects the quality of daily life. Action regulation is a critical executive function (cognitive control over behavior), which includes actions such as suppressing activity when selecting between options, making decisions about stopping unwanted or inappropriate actions, and switching to new actions in response to environmental changes. Parkinson's disease (PD) has been shown to disrupt action inhibition which can be considered a measure to the progression of PD. The purpose of this research study is to better understand the mechanism of action regulations in PD patients and how action regulations in PD can be improved using dopaminergic treatment, which is a drug that either releases or involves dopamine, which is a neurotransmitter involved in sending signals to nerve cells. You are asked to participate in this research study because you are receiving a dopaminergic medication for treatment of your Parkinson's disease. There is currently no theory that integrates the mechanisms of action regulation into a unified framework, which this study aims to address. The researchers hope to learn more about the mechanisms of action regulation in PD patients and to help decrease action regulation disruptions in PD patients. This study will help characterize the motor behavior of PD patients.

Official Title

Revealing the Action Regulation Mechanisms in the Human Brain

Quick Facts

Study Start:2024-04-24
Study Completion:2024-12-13
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06489483

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of Parkinson's Disease by a movement disorder neurologist
  2. * Levodopa responsive with clearly defined "on" periods, with at least 30% improvement in UPDRS III scores on vs off
  3. * Willingness and ability to complete the behavioral experiments for up 3.5 hours
  4. * No vision or hearing problems that impair ability to participate with the proposed tasks as assessed by the study investigators
  1. * Patients with history of secondary Parkinsonism, stroke, or progressive central nervous system disease other than Parkinson's Disease
  2. * Patients with a disease or condition that prevents understanding or communication of informed consent, study demands, and testing protocol including cognitive decline, diagnosed forms of dementia, significant memory impairment (MoCA\<23), or hearing loss that prevents adequate communication with researcher

Contacts and Locations

Study Contact

Nader Pouratian, MD, Phd
CONTACT
(214) 645-5465
nader.pouratian@utsouthwestern.edu
Sahil Chilukuri, BS
CONTACT
(214) 645-5465
sahil.chilukuri@utsouthwestern.edu

Study Locations (Sites)

University of Texas Southwestern Medical Center
Dallas, Texas, 75390
United States

Collaborators and Investigators

Sponsor: University of Texas Southwestern Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-24
Study Completion Date2024-12-13

Study Record Updates

Study Start Date2024-04-24
Study Completion Date2024-12-13

Terms related to this study

Keywords Provided by Researchers

  • Levodopa medication
  • motor cortex
  • basal ganglia

Additional Relevant MeSH Terms

  • Parkinson Disease